Maxim Group Maintains Buy On Soligenix Following A Successful Study On The Company’s RiVax Vaccine
In a research report released today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Soligenix (SNGX) with a $3 price target, following the company’s successful study for its RiVax vaccine, which demonstrated that non-human primates vaccinated with RiVax™ were completely protected against a lethal aerosol of ricin toxin with a highly significant survival benefit (p<0.002).
Kolbert wrote, “With active Biodefense programs in anthrax, ricin, and acute radiation syndrome, we see Soligenix as positioned to capture DOD/BARDA contracts. In a crisis, we could see value realized as investors focus on which companies have solutions, in much the way recent events in West Africa have focused attention on those companies developing Medical Counter Measures (MCM) to Ebola.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 17.3% and a 64.3% success rate. Kolbert has an average return when recommending SNGX, and is ranked #113 out of 3263 analysts.